Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Ex-a7878
2. 2805997-46-8
Molecular Weight | 4232 g/mol |
---|---|
Molecular Formula | C192H289N47O61 |
XLogP3 | -14.1 |
Hydrogen Bond Donor Count | 62 |
Hydrogen Bond Acceptor Count | 66 |
Rotatable Bond Count | 149 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 1760 |
Heavy Atom Count | 300 |
Formal Charge | 0 |
Complexity | 10100 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 32 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by...
About the Company : Shenzhen JYMed Technology Co.,Ltd is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides based products, including active ph...
Details:
The net proceeds will strengthen Zealand’s investment in assets targeting obesity, including BI 456906 (survodutide), a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly administration.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 456906
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Carnegie Investment Bank
Deal Size: $214.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 01, 2024
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Carnegie Investment Bank
Deal Size : $214.0 million
Deal Type : Private Placement
Zealand Pharma Raises DKK 1.45 Billion in Directed Issue and Private Placement
Details : The net proceeds will strengthen Zealand’s investment in assets targeting obesity, including BI 456906 (survodutide), a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly administration.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Undisclosed
August 01, 2024
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BI 456906
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Boehringer Ingelheim GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2024
Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand, Boehringer Win FDA Breakthrough Status to Treat Fatty Liver
Details : BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
July 10, 2024
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BI 456906
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 06, 2024
Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer's Survodutide Shows Improvement in Liver Fibrosis
Details : BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
July 06, 2024
Details:
BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Boehringer Ingelheim GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Survodutide Phase II shows 83% of adults treated achieved groundbreaking results
Details : BI456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action. It is being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
February 26, 2024
Details:
Boehringer Ingelheim is developing BI 456906, a novel glucagon receptor/GLP-1 receptor dual agonist, for the treatment of people living with overweight or obesity as well as for the treatment people living with of Nonalcoholic Steatohepatatis (NASH).
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Zealand Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2023
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Boehringer Ingelheim is developing BI 456906, a novel glucagon receptor/GLP-1 receptor dual agonist, for the treatment of people living with overweight or obesity as well as for the treatment people living with of Nonalcoholic Steatohepatatis (NASH).
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
October 05, 2023
Details:
Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 17, 2023
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim to Advance Survodutide into Three Global Phase III Studies in Obesity
Details : Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
August 17, 2023
Details:
BI 456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 456906
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Zealand Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2023
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
May 10, 2023
Details:
BI 456906 is a dual agonist, acting on glucagon (GCG) receptors and glucagon-like peptide-1 (GLP-1) receptors to regulate energy and glucose homeostasis, and which is expected to improve the metabolic profile of treated individuals.
Lead Product(s): Survodutide
Therapeutic Area: Endocrinology Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Boehringer Ingelheim GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2022
Lead Product(s) : Survodutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 456906 is a dual agonist, acting on glucagon (GCG) receptors and glucagon-like peptide-1 (GLP-1) receptors to regulate energy and glucose homeostasis, and which is expected to improve the metabolic profile of treated individuals.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
September 21, 2022
Details:
The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.
Lead Product(s): Survodutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Zealand Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2021
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Details : The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
April 13, 2021
Details:
The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Lead Product(s): Survodutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BI 456906
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Zealand Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2021
Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2021
https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-feb-2024-novo-s-parent-buys-catalent-for-us-16-5-bn-fda-okays-iovance-s-cell-therapy
ABOUT THIS PAGE
26
PharmaCompass offers a list of Survodutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Survodutide manufacturer or Survodutide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Survodutide manufacturer or Survodutide supplier.
PharmaCompass also assists you with knowing the Survodutide API Price utilized in the formulation of products. Survodutide API Price is not always fixed or binding as the Survodutide Price is obtained through a variety of data sources. The Survodutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Survodutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Survodutide, including repackagers and relabelers. The FDA regulates Survodutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Survodutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Survodutide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Survodutide supplier is an individual or a company that provides Survodutide active pharmaceutical ingredient (API) or Survodutide finished formulations upon request. The Survodutide suppliers may include Survodutide API manufacturers, exporters, distributors and traders.
click here to find a list of Survodutide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Survodutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Survodutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Survodutide GMP manufacturer or Survodutide GMP API supplier for your needs.
A Survodutide CoA (Certificate of Analysis) is a formal document that attests to Survodutide's compliance with Survodutide specifications and serves as a tool for batch-level quality control.
Survodutide CoA mostly includes findings from lab analyses of a specific batch. For each Survodutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Survodutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Survodutide EP), Survodutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Survodutide USP).